Department of Pathology
Department of Nuclear Medicine & PET Research
VU University Medical Center
PO Box 7057
1007 MB Amsterdam
The Netherlands
phone: +31 20 4442 395
e-mail: ja.goos@vumc.nl
Current research is focused on the development of new poitron emission tomography (PET) tracers for patients with metastatic colorectal cancer. In several medical institutes in The Netherlands both tissue samples and corresponding clinicopathological data of these patients is collected and tissue samples are incorporated into tissue microarrays (TMAs). Using immunohistochemical techniques (new) prognostic biomarkers are identified, potentially qualifying for imaging of lesions in patients with metastatic colorectal cancer. Simultaneously, the prognostic relevance of 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) as a tracer for PET in liver metastases of colorectal cancer is determined in a multicenter clinical trial: the PICO trial (“Prognostic Imaging COlorectal Cancer”). In total 17 institutes are involved in this project, which was supported by the Center for Translational Molecular Medicine ( www.ctmm.nl ).
All participants in the study are included in the “DeCoDe PET” group and can be found here .
After obtaining his Master’s degree in Medical Engineering at the Eindhoven University of Technology, where he has worked both on the synthesis of multilayered biomimetic minerals and on the development of environmental-dependent nanocarriers for drug targeting, both in collaboration with the University of Manchester, Jeroen Goos started his PhD at the VU University Medical Center in Amsterdam in 2009. In a collaboration between the Pathology Department (Prof. Dr. Gerrit A. Meijer) and the Nuclear Medicine & PET Research Department (Prof. Dr. Otto S. Hoekstra), he now is working on the development of new positron emission tomography (PET) tracers for patients with metastatic colorectal cancer.
Click for recent publications .